RAHWAY, N.J. & KINGSTON, Ontario–(BUSINESS WIRE)– Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and the Canadian Cancer Trials Group (CCTG) today announced that the Phase 2/3 CCTG IND.227/KEYNOTE-483 trial evaluating KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with chemotherapy met its primary endpoint of overall survival (OS) for the first-line treatment of patients with unresectable advanced or metastatic malignant pleural mesothelioma. IND.227 was sponsored by CCTG, in collaboration with investigators in Italy (co-sponsored by National Cancer Institute of Naples – NCIN), and France (co-sponsored by The French Cooperative Thoracic Intergroup – IFCT); Merck provided KEYTRUDA and support for the trial. At the final analysis of the study, KEYTRUDA plus chemotherapy showed a statistically significant and clinically meaningful improvement in OS compared to chemotherapy alone in these patients. The safety profile of KEYTRUDA in combination with chemotherapy in this study was consistent with previously reported studies. Results will be presented at an upcoming medical meeting and discussed with regulatory authorities worldwide.
An ASCO expert panel has developed a comprehensive guideline for immunotherapy and targeted therapy in patients with advanced gastroesophageal cancer.1 The guideline is based on the many recent advances in immunotherapy and targeted therapy. “The role of immunotherapy has changed practice in the past 18 months, so this topic is very timely,” said lead author and Expert Panel Co-Chair Manish Shah, MD, of Weill Cornell Medicine.
Read More>
The FDA has cleared an investigational new drug (IND) application to evaluate BA3182 for the treatment of patients with advanced adenocarcinoma, according to BioAtla, Inc.
As a result of the IND, the company plans to initiate and advance a phase 1 dose-escalation and dose-expansion clinical trial in 2023, which will evaluate the safety, pharmacokinetics, and efficacy of BA3182 in patients with advanced adenocarcinoma.
Positive results reported by Astellas Pharma regarding its novel Claudin 18.2-targeting antibody, zolbetuximab, suggest that an approval in front-line gastric and gastroesophageal junction (GEJ) adenocarcinoma is not far off. Two Phase III studies, SPOTLIGHT (NCT03504397) and GLOW (NCT03653507), examined the efficacy of monoclonal antibody zolbetuximab in patients deemed to have high expression of Claudin 18.2 (characterised as more than 75% of tumour cells with moderate to high expression, as measured by immunohistochemical assay) versus traditional chemotherapy (FOLFOX6 in SPOTLIGHT and CAPOX in GLOW).
The KEYNOTE-859 trial is evaluating Keytruda in combination with fluoropyrimidine- and platinum-containing chemotherapy in 1,579 patients with HER2-negative locally advanced unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma.
Gastric cancer is the fifth most diagnosed cancer and the fourth leading cause of cancer deaths worldwide, with nearly 1.1 million new cases diagnosed and more than 768,000 deaths from the disease globally in 2020. Most gastric cancers are adenocarcinomas, which develop from cells in the innermost lining of the stomach.
Diagnosing gastrointestinal disorders is an uncomfortable process. It might involve sticking a long tube with a camera attached down a patient’s throat, or inserting a small catheter through a patient’s nostril.
BOSTON, Ma. – Fifty-four-year-old Beth Lambert comes from a big family. She’s one of five siblings, but in 2006, her brother Steve died from a rare form of stomach cancer.
“Just watching our brother go from someone who was so full of life, and he really was as much as he could be up until the end,” remembered Beth.
BALTIMORE —In this Woman’s Doctor segment, we take a closer look at stomach cancer. It’s a disease increasing among Americans under 50, particularly women. That’s according to a study by the National Cancer Institute which tracked the incidence of lower stomach cancer in the United States. Mercy Medical Center Dr. Vadim Gushchin said the incidence of gastric cancer is very low in the U.S. and found the study result a bit surprising and he joins us with more information.
The rate of stomach cancer is increasing among Americans under 50, particularly women, according to a study by the National Cancer Institute. Researchers tracked the incidence of lower stomach cancer in the United States. Mercy Medical Center surgical oncologist Dr. Vadim Gushchin said the incidence of gastric cancer is very low in the U.S. and found the study results a bit surprising. The study also found women are affected more by autoimmune diseases, which can also lead to cancer.
The American Society of Clinical Oncology (ASCO) has released new guidelines providing recommendations for the optimal treatment of patients with advanced gastroesophageal cancer following a systemic review of 18 randomized controlled trials by an expert panel.